Able Cerebral
Biotechnology, 55 New St, Ephrata, Pennsylvania, 17522, United States, 1-10 Employees
Who is ABLE CEREBRAL
Able Cerebral, LLC (ACL) is located in Ephrata, Pennsylvania, USA. ACL owns US, Canada and Chinese patents and patent applications. Innovation in technologies and therapeutic methods are ...
Read More
- Headquarters: 55 New St, Ephrata, Pennsylvania, 17522, United States
- Date Founded: 2012
- Employees: 1-10
- Revenue: Under $1 Million
- Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8399
Does something look wrong? Fix it. | View contact records from ABLE CEREBRAL
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Able Cerebral
Answer: Able Cerebral's headquarters are located at 55 New St, Ephrata, Pennsylvania, 17522, United States
Answer: Able Cerebral's official website is https://ablecerebral.com
Answer: Able Cerebral's revenue is Under $1 Million
Answer: Able Cerebral's SIC: 8399
Answer: Able Cerebral has 1-10 employees
Answer: Able Cerebral is in Biotechnology
Answer: Able Cerebral contact info: Phone number: Website: https://ablecerebral.com
Answer: Able Cerebral, LLC (ACL) is located in Ephrata, Pennsylvania, USA. ACL owns US, Canada and Chinese patents and patent applications. Innovation in technologies and therapeutic methods are among the core values of the company. ACL is a unique worldwide leader in timed brain energy delivery and circadian / chronotherapy for CNS diseases. ACL is currently transforming into a bio-pharmaceutical and medical device entity. ACLs 1st innovative product BrainGlucose since 2013, has saved precious memories for Alzheimer's, diabetics, cancer patients on Chemo, and Parkinson's patients; the 2nd product under development AddMem (Alzheimer's disease & dementia Memory enhancing method) would be also a breakthrough therapeutic system (Device) in the world for memory retain and recovery for late stage Alzheimer's disease and Traumatic Brain Injury (TBI). ACL is proud to announce that, our first product BrainGlucose has gained great reputation within Alzheimer's patients and their caregivers. It stops AD patients nightmares, night sweats, and early morning hallucinations so they will not deteriorate to late stage and keep their dignity and relatively independent lifestyle. BrainGlucose has also been loved by many diabetics to prevent noctunal hypoglycemia (post midnight low blood sugar), and weight gain. ACL is actively seeking investment and joint ventures to co-develop our brain energy product and memory recovery project by applying for FDA approval as breakthrough drugs and non invasive medical device (AddMem).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month